newsfilter
← Latest News
GlobeNewswire·

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BLSM
  • BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) announced presentations at the 8th Annual RAS-Targeted Drug Development Summit & the H.C. Wainwright 28th Annual Global Investment Conference.
  • Dr. Geoff Oxnard, Chief Medical Officer, will present at the RAS-Targeted Drug Development Summit held on Thursday, September 10 at The Colonnade Hotel in Boston.
  • Dr. Jean Cui, Founder, President & CEO, will present at the H.C. Wainwright conference held on Tuesday, September 15 at the Lotte New York Palace Hotel in New York City.
  • Dr. Cui & management team members will be available for one-on-one meetings at the H.C. Wainwright conference.
  • Webcast access for the H.C. Wainwright conference is available via the company's Investor Relations website, with an archived replay accessible for 90 days.
  • The company's lead clinical program is BH-30643, a mutant-selective OMNI-EGFR inhibitor for EGFR-mutant NSCLC that received Fast Track designation for the C797S resistance population.
  • BlossomHill is developing BH-30236, a macrocyclic CLK inhibitor for relapsed or refractory AML & higher-risk MDS.
  • The pipeline includes BH-501284, a preclinical pan-KRAS Switch II inhibitor for potential development in KRAS-mutant tumors.
  • BlossomHill Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California.